Chinese prostate, breast cancer drugs maker Kintor’s IPO more than 500 times oversubscribed as Hong Kong biotech investment fever continues

, , Comments Off on Chinese prostate, breast cancer drugs maker Kintor’s IPO more than 500 times oversubscribed as Hong Kong biotech investment fever continues

Cancer drugs developer Kintor Pharmaceutical saw its HK$1.86 billion (US$240 million) initial public offering heavily oversubscribed as investors continued to bet on biotech start-ups hitting the …
( read original story …)